Cardiac Dimensions^®, Inc. is an early stage, venture-backed company developing a minimally invasive implantable product to treat mitral valve regurgitation associated with congestive heart failure (CHF). This percutaneous approach to annuloplasty is accomplished by implanting a device in the great cardiac vein / coronary sinus via a catheter-based delivery system. The implant is designed to reshape the mitral annulus
that surrounds the valve and reduce the
mitral regurgitation.

More than 21 million people worldwide suffer
from CHF, with more than 5 million cases in the U.S., and the number is growing rapidly. The development of mitral valve regurgitation is common in these patients and contributes significantly to the morbidity and mortality of people with CHF.